Business
Innate Pharma Reports First Quarter 2026 Business Update and Financial Results
MARSEILLE, France, May 13, 2026--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today reported its business update and consolidated financial results for the quarter ending March 31, 2026.
About this update from Innate Pharma Sa Class A
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/3d8d406099027d9b1b3b3725f438496c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QFab2EYMyLEMb1JhkTl8ng--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/3d8d406099027d9b1b3b3725f438496c","width":960,"height":480},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/U7PkkxwdhF4Qizt5FPLs0A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTMyMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/3d8d406099027d9b1b3b3725f438496c","width":640,"height":320},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/QLAkrV6gGV9dxBKl3zu06g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/3d8d406099027d9b1b3b3725f438496c","width":1024,"height":512}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Lacutamab TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma (CTCL) remains planned for initiation in H2 2026, subject to non-dilutive financing options currently under negotiation, including pharma partnering and royalty structures","length":248,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"IPH4502 (Nectin-4 ADC) continues to show preliminary anti-tumor activity with favorable safety profile to date; the maximum tolerated dose has been reached and enrollment in the Phase 1 dose escalation and cohort enrichment is nearing completion","length":245,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"PACIFIC-9 Phase 3 trial, which includes monalizumab and is led by AstraZeneca, continues to advance toward a planned H2 2026 data readout","length":137,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"IPH5201 (anti-CD39 antibody), developed in collaboration with AstraZeneca, showed encouraging early results presented in a Clinical Trials Plenary Session at AACR 2026, supporting continued investigation in the MATISSE Phase 2 study in non-small cell lung cancer (NSCLC)","length":270,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Cash position of €25.4 million1 as of March 31, 2026, with an anticipated cash runway until the end of Q3 2026","length":110,"tagName":"p","attri...